Thermo Fisher Reports Completion of Acquisition of The Binding Site at ~$2.8B
Shots:
- The acquisition is completed from a shareholder group led by Nordic Capital, in an all-cash transaction valued at $2.8B at current exchange rates
- In Oct 2022, the acquisition was initiated and the transaction is expected to be adjusted per share by $0.07 in 2023. Also ~1200 employees of The Binding Site will be part of Thermo Fisher's Diagnostics segment
- The acquisition will lead to expand Thermo Fisher’s diagnostics pipeline through innovation and monitoring for multiple myeloma by using Freelite’s offerings
Ref: Businesswire | Image: Thermo Fisher
Related News:- Thermo Fisher’s Oncomine Dx Target Test Receives the US FDA's Approval as a NGS-Based CDx for the Treatment of NSCLC
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
